All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Outcomes of patients with AML treated with intensive chemotherapy during 1997–2016: A HARMONY Alliance analysis
Bookmark this article
|
A retrospective analysis assessed the outcomes of patients with AML treated with intensive chemotherapy over four consecutive 5-year calendar periods, 1997–2001 (n = 1,127), 2002–2006 (n = 1,294), 2007–2011 (n = 1,821), and 2012–2016 (n = 1,117), using the HARMONY Alliance database.1 Results from this analysis were published in Haematologica by Sobas et al.1 |
| Key learnings |
| Median OS improved from 15.5 months to 37.8 months over the four calendar periods (p < 0.0001), likely due to a reduction in the early death rate within 60 days of diagnosis from 13.0% to 4.7% (p < 0.0001). |
| Improved OS over time was observed across all patient age groups, genetic risk groups, and in patients treated both with or without allo-HSCT consolidation. |
| Allo-HSCT was associated with a survival advantage in patients aged ≥60 years (p < 0.0001), emphasizing its role as a critical consolidative therapy, even for older populations. |
| Results from this analysis highlighted the improved outcomes in intensively treated patients with AML during 1997–2016, likely due to better therapy management and supportive care, increased referrals for allo-HSCT, and safer application of allo-HSCT in older patients. |
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation, AML, acute myeloid leukemia; OS, overall survival.
- Sobas MA, Turki AT, Ramiro AV, et al. Outcomes with intensive treatment for acute myeloid leukemia: An analysis of two decades of data from the HARMONY Alliance. 2024. Online ahead of print. DOI: 10.3324/haematol.2024.285805
More about...
Your opinion matters
29 votes - 39 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox